CA2567655C - Binding moieties based on shark ignar domains - Google Patents

Binding moieties based on shark ignar domains Download PDF

Info

Publication number
CA2567655C
CA2567655C CA2567655A CA2567655A CA2567655C CA 2567655 C CA2567655 C CA 2567655C CA 2567655 A CA2567655 A CA 2567655A CA 2567655 A CA2567655 A CA 2567655A CA 2567655 C CA2567655 C CA 2567655C
Authority
CA
Canada
Prior art keywords
domain
atom
remark
loop
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2567655A
Other languages
English (en)
French (fr)
Other versions
CA2567655A1 (en
Inventor
Stewart Nuttal
Victor Streltsov
Katherine Merne Griffiths
Jennifer Ann Carmichael
Peter Hudson
Robert Alexander Irving
Joseph Noozhumutry Varghese
Miles Mackay Barraclough
David Peter Simmons
Kylie Anne Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adalta Ltd
Original Assignee
Adalta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adalta Ltd filed Critical Adalta Ltd
Publication of CA2567655A1 publication Critical patent/CA2567655A1/en
Application granted granted Critical
Publication of CA2567655C publication Critical patent/CA2567655C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2567655A 2004-06-02 2005-06-02 Binding moieties based on shark ignar domains Active CA2567655C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57584504P 2004-06-02 2004-06-02
US60/575,845 2004-06-02
PCT/AU2005/000789 WO2005118629A1 (en) 2004-06-02 2005-06-02 BINDING MOIETIES BASED ON SHARK IgNAR DOMAINS

Publications (2)

Publication Number Publication Date
CA2567655A1 CA2567655A1 (en) 2005-12-15
CA2567655C true CA2567655C (en) 2015-06-30

Family

ID=35462883

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2567655A Active CA2567655C (en) 2004-06-02 2005-06-02 Binding moieties based on shark ignar domains

Country Status (7)

Country Link
US (3) US7977071B2 (ja)
EP (3) EP2330120A3 (ja)
JP (2) JP2008511286A (ja)
AU (3) AU2005250055B2 (ja)
CA (1) CA2567655C (ja)
DK (2) DK2330121T3 (ja)
WO (1) WO2005118629A1 (ja)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009004065A2 (en) 2007-07-03 2009-01-08 Ablynx N.V. Providing improved immunoglobulin sequences by mutating cdr and/or fr positions
WO2009026638A1 (en) * 2007-08-31 2009-03-05 Melbourne Health Marine-animal derived therapeutic and diagnostic agents for hepatitis b
JP2011529171A (ja) 2008-07-25 2011-12-01 セレスティス リミテッド 診断方法
US20100136584A1 (en) * 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
US20100092470A1 (en) * 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
WO2010040175A1 (en) * 2008-10-06 2010-04-15 Commonwealth Scientific And Industrial Research Organisation Amyloid-beta peptide crystal structure
EP2427489B1 (en) 2009-05-07 2015-04-22 Novozymes Biopharma DK A/S Method of controlling o-linked glycosylation of antibodies
EP2448966B1 (en) 2009-07-03 2018-11-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
WO2011056056A2 (es) 2009-11-04 2011-05-12 Laboratorios Silanes, S.A. De C.V. Dominios vhnar anti -citocinas
US9459253B2 (en) 2009-12-23 2016-10-04 Cellestis Limited Assay for measuring cell-mediated immunoresponsiveness
AU2010336029B2 (en) 2009-12-23 2011-10-13 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
WO2012122590A1 (en) 2011-03-14 2012-09-20 Cellmid Limited Antibody recognizing n-domain of midkine
EP2702165B1 (en) 2011-04-29 2017-03-22 Cellestis Limited An assay of cell mediated immune responsiveness
AU2012269720B2 (en) 2011-06-13 2015-01-22 Csl Limited Antibodies against G-CSFR and uses thereof
EP3351936A1 (en) 2011-06-29 2018-07-25 Cellestis Limited A cell mediated immune response assay with enhanced sensitivity
CA2852709A1 (en) 2011-10-28 2013-05-02 Patrys Limited Pat-lm1 epitopes and methods for using same
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US10112988B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
MX347154B (es) * 2012-02-24 2017-02-21 Centro De Investigación Científica Y De Educación Superior De Ensenada Baja California (Cicese) Prueba de diagnóstico para enfermedades infecciosas en ganado bovino.
US20130302250A1 (en) 2012-05-07 2013-11-14 The University Court Of The University Of Aberdeen Single domain binding molecule
WO2014100853A1 (en) 2012-12-28 2014-07-03 Cellestis Limited A cell mediated immune response assay
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
WO2014122144A1 (en) 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
JP6545105B2 (ja) 2013-02-07 2019-07-17 シーエスエル、リミテッド Ｉｌ−１１ｒ結合タンパク質及びその使用
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
RU2015146419A (ru) 2013-04-23 2017-05-26 Зе Юниверсити Корт Оф Зе Юниверсити Оф Абердин Выделение терапевтических доменов vnar, специфичных по отношению к мишени icosl
DK3074038T3 (en) 2013-11-28 2019-03-11 Csl Ltd METHOD OF TREATING DIABETIC NEPHROPATHY
JP6553618B2 (ja) 2013-12-18 2019-07-31 シーエスエル リミティド 創傷を治療する方法
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
EP3133085A1 (en) * 2014-04-17 2017-02-22 Teraclón Idf, S.L. Vnar recombinant monoclonal antibodies that neutralize vascular endophelial growth factor vegf
JP6454981B2 (ja) * 2014-04-24 2019-01-23 住友電気工業株式会社 半導体積層体および受光素子
JP6355020B2 (ja) * 2014-05-14 2018-07-11 パナソニックＩｐマネジメント株式会社 目元用美容装置
EP3160995A2 (en) 2014-06-26 2017-05-03 Ossianix Inc. Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
KR20240045370A (ko) 2014-10-23 2024-04-05 퀴아젠 사이언시스, 엘엘씨 펩티드 조성물 및 그의 용도
EP3209697A4 (en) 2014-10-23 2018-05-30 La Trobe University Fn14-binding proteins and uses thereof
CA2967830A1 (en) 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
JP6863897B2 (ja) 2015-01-09 2021-04-21 アダルタ・リミテッド Ｃｘｃｒ４結合分子
EP3302457A2 (en) 2015-06-08 2018-04-11 Lophius Biosciences GmbH Composition for determination of cell-mediated immune responsiveness
EA036975B1 (ru) 2015-08-03 2021-01-21 Энгмаб Сарл Моноклональные антитела против bcma
EP3816294A1 (en) 2015-09-11 2021-05-05 Biosceptre (UK) Limited Chimeric antigen receptors and uses thereof
US10273196B2 (en) 2015-09-25 2019-04-30 Exxonmobil Chemical Patents Inc. Hydrocarbon dehydrocyclization
AU2017259876A1 (en) 2016-05-02 2018-10-25 Ablynx Nv Treatment of RSV infection
AU2017331739A1 (en) 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
CN110325547B (zh) 2016-11-07 2023-12-26 德格克斯有限公司 新淀粉样蛋白β寡聚体特异性结合分子
US11155612B2 (en) 2017-04-21 2021-10-26 Centro De Investigación Científica Y De Educación Superior De Ensenada, Baja California vNAR antibody which binds VEGF for use in dogs or cats
NZ760841A (en) 2017-07-11 2024-02-23 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CA3075367A1 (en) 2017-09-27 2019-04-04 Elasmogen Ltd Specific binding molecules
US20200354452A1 (en) 2017-09-29 2020-11-12 City Of Hope Cars and bispecific antibodies for treatment of mantle cell lymphoma
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US11180544B2 (en) * 2017-11-07 2021-11-23 City University Of Hong Kong Method of producing antibody fragment
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
AU2018377856A1 (en) 2017-11-29 2020-05-21 Csl Limited Method of treating or preventing ischemia-reperfusion injury
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
EP3877399A4 (en) 2018-11-06 2022-10-19 Alsatech, Inc. CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES
CA3119161A1 (en) 2018-11-13 2020-05-22 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
WO2022035998A1 (en) 2020-08-11 2022-02-17 City Of Hope Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
GB202020152D0 (en) 2020-12-18 2021-02-03 Elasmogen Ltd Fast-track humanisation of specific binding molecules
WO2023092177A1 (en) * 2021-11-23 2023-06-01 Adalta Limited Rank-l binding molecules
WO2024008904A2 (en) 2022-07-08 2024-01-11 Novo Nordisk A/S Highly potent isvd compounds capable of substituting for fviii(a)
CN116284423B (zh) * 2022-12-29 2023-10-03 江苏百英生物科技有限公司 一种靶向条纹斑竹鲨IgNAR-CH1多克隆抗体、其制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP2919890B2 (ja) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
GB8927230D0 (en) 1989-12-01 1990-01-31 Unilever Plc Reagents
US5955363A (en) 1990-01-03 1999-09-21 Promega Corporation Vector for in vitro mutagenesis and use thereof
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP1295952A3 (en) 1996-01-23 2003-07-09 The Board of Trustees of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU747637B2 (en) * 1998-03-06 2002-05-16 Arana Therapeutics (Vic) Pty Ltd V-like domain binding molecules
JP2004526419A (ja) * 2000-10-16 2004-09-02 フィロス インク． 抗体模倣物および他の結合タンパク質のためのタンパク質骨格
EP1419179B1 (en) * 2001-08-10 2010-03-03 Aberdeen University Antigen binding domains from fish
ATE290020T1 (de) * 2001-08-31 2005-03-15 Avidex Ltd Löslicher t zell rezeptor
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20040266993A1 (en) * 2003-06-30 2004-12-30 Evans Glen A. Non-immunoglobulin binding polypeptides

Also Published As

Publication number Publication date
EP2330120A3 (en) 2011-11-16
US20160237169A1 (en) 2016-08-18
EP2330121A2 (en) 2011-06-08
AU2008229687B2 (en) 2009-01-29
CA2567655A1 (en) 2005-12-15
AU2008229687A1 (en) 2008-10-30
DK2330121T3 (en) 2014-12-15
WO2005118629A1 (en) 2005-12-15
AU2009201692A1 (en) 2009-05-21
AU2005250055B2 (en) 2008-09-11
EP2330120A2 (en) 2011-06-08
EP1751181A4 (en) 2008-03-12
US7977071B2 (en) 2011-07-12
EP1751181A1 (en) 2007-02-14
EP2330121B1 (en) 2014-09-03
JP2008511286A (ja) 2008-04-17
AU2009201692B2 (en) 2012-08-30
EP1751181B1 (en) 2012-08-15
DK1751181T3 (da) 2012-11-26
US20120003214A1 (en) 2012-01-05
US20090148438A1 (en) 2009-06-11
EP2330121A3 (en) 2011-11-16
AU2005250055A1 (en) 2005-12-15
JP5631812B2 (ja) 2014-11-26
JP2011244822A (ja) 2011-12-08

Similar Documents

Publication Publication Date Title
CA2567655C (en) Binding moieties based on shark ignar domains
AU759378B2 (en) Three-dimensional structures and models of Fc receptors and uses thereof
Korndörfer et al. Structural mechanism of specific ligand recognition by a lipocalin tailored for the complexation of digoxigenin
WO2003035846A2 (en) Structure of tall-1 and its cognate receptor
WO2008021379A2 (en) Increased activity and efficiency of expansin-like proteins
Hulsmeyer et al. A major histocompatibility Complex· Peptide-restricted antibody and T cell receptor molecules recognize their target by distinct binding modes: CRYSTAL STRUCTURE OF HUMAN LEUKOCYTE ANTIGEN (HLA)-A1· MAGE-A1 IN COMPLEX WITH FAB-HYB3
WO2008068534A2 (en) Crystal structure of a betal -adremergi c receptor and uses thereof
Ramsland et al. Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody
Wurzburg et al. Conformational flexibility in immunoglobulin E-Fc3–4 revealed in multiple crystal forms
AU2012258331B2 (en) Binding moieties based on shark IgNAR domains
WO2007075414A2 (en) Chemically derivatized cd4 and uses thereof
MX2008015580A (es) Metodos para identificar imitadores de toxina de araña especificos para insectos.
CA2594890A1 (en) Estrogen receptor structure
AU770150B2 (en) Three-dimensional model of a FC epsilon receptor alpha chain and uses thereof
AU8871198A (en) Crystal of sm3 antibody (fragment) and recognizing epitope, its preparation, encoded data storage medium containing its coordinates and its diagnostical or medical use
Rudolph et al. Crystal structure of an isolated Vα domain of the 2C T-cell receptor
Scheerer et al. Structure of an anti‐cholera toxin antibody Fab in complex with an epitope‐derived D‐peptide: a case of polyspecific recognition
WO2012037150A1 (en) Crystal structures of o-glcnac transferase and uses thereof
Diestel Structural Basis for TGF-β-Receptor Interaction and Antibody Recognition of HCMV Envelope Protein gB
WO2007021342A2 (en) Crystal of a transporter-ligand complex and methods of use
WO2017174762A1 (en) Crystal structure of human dopamine beta-hydroxylase

Legal Events

Date Code Title Description
EEER Examination request